HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Key facts

Sponsor

Medigene AG

Principal Investigator

Peter van Balen, MD

Leiden University Medical Centre

Intervention

MDG1021 dose 1(drug)

Eligibility

18 years · All sexes

Timeline

2020 – 2025

Study locations (1)

• Leiden University Medical Centre, Leiden, South Holland, Netherlands

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute panmyelosis with myelofibrosis

Additional recruiting or active studies for the same condition.

• RECRUITINGEARLY PHASE1NCT06398457
  Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• RECRUITINGNANCT05875805
  A Telehealth Advance Care Planning Intervention
  University of Rochester
• ACTIVE NOT RECRUITINGPHASE1NCT05455294
  Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
  Jacqueline Garcia, MD
• RECRUITINGPHASE1NCT04771572
  Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
  Newave Pharmaceutical Inc
• ACTIVE NOT RECRUITINGPHASE2NCT04060277
  Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
  City of Hope Medical Center
• ACTIVE NOT RECRUITINGPHASE3NCT03480360
  Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
  Dartmouth-Hitchcock Medical Center

See all trials for Acute panmyelosis with myelofibrosis →